Results 91 to 100 of about 13,114,410 (297)

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

open access: yesMolecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis   +3 more
wiley   +1 more source

Trust negotiation and service level agreements

open access: yes, 2009
Providing effective Grid resource allocation mechanisms is a key factor in realising the Grid vision. In this talk, we present the SLA negotiation component developed in the Ontogrid project.
Paurobally, S.
core  

The effectiveness of non-governmental organizations in enhancing social welfare services: A case study of SOS Children’s Village [PDF]

open access: yesE-Journal of Humanities, Arts and Social Sciences
This study examines the role of non-governmental organisations (NGOs) in enhancing social welfare services, with a specific focus on the SOS Children’s Village in the Eastern Cape province.
Akhona Matutyana   +2 more
doaj   +1 more source

Precise service level agreements [PDF]

open access: yesProceedings. 26th International Conference on Software Engineering, 2004
James Skene   +2 more
openaire   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

The New Metric and the New Software Tool for Determining QoS in the Short Messages Service in Mobile Networks

open access: yesJournal of Telecommunications and Information Technology, 2017
With traveling professions and nomadic lifestyles on the increase there is a growing need for comprehensive mobile networking within the Next Generation Network, and the security, reliability and technical independency of the Short Message Service (SMS)
Marcus Rompf, Tadeus Uhl
doaj   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

open access: yesMolecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu   +3 more
wiley   +1 more source

PROBLEMS AND PROSPECTS OF INTERNATIONAL TRADE LICENSES IN UKRAINE

open access: yesEkonomìčnij Vìsnik Nacìonalʹnogo Tehnìčnogo Unìversitetu Ukraïni "Kiïvsʹkij Polìtehnìčnij Institut", 2015
It was analysed international trade licenses on a global level, determined country and sector, which occupy a significant share of the market license.
Алла Рашидівна Дунська   +1 more
doaj   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

open access: yesMolecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy